Northwest Biotherapeutics Inc (QB)【NWBO】株式ニュース

	リアルタイム株価	レベル2
Forex

個人投資家向けのプロ仕様のツール。

Form 8-K - Current report

Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia

Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia Miami, FL -- (InvestorsHub...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Miami, FL-- (InvestorsHub NewsWire – November 9, 2023) –...

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo Miami, FL-- (InvestorsHub NewsWire –...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Nightfood, Inc. (OTCQB: NGTF) now in Sonesta International Hotels Multiple Brands

Nightfood, Inc. (OTCQB: NGTF) now in Sonesta International Hotels Multiple Brands Nightfood, Inc. (OTCQB: NGTF) just announced that it has...

Annual Report (10-k)

0001072379--12-312022FYfalseNONE014000001068400000948400000http://fasb.org/us-gaap/2022#DerivativeGainLossOnDeri...

Annual Statement of Changes in Beneficial Ownership (5)

FORM 5 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Current Report Filing (8-k)

0001072379 false --12-31 0001072379 2023-01-09 2023-01-09 iso4217:USD...

Current Report Filing (8-k)

0001072379 false 0001072379 2022-12-30 2022-12-30 iso4217:USD xbrli:shares...

Additional Proxy Soliciting Materials (definitive) (defa14a)

As filed with the Securities and Exchange Commission on December [XX], 2022 SCHEDULE 14A...

Additional Proxy Soliciting Materials (definitive) (defa14a)

As filed with the Securities and Exchange Commission on December 16, 2022 SCHEDULE 14A...

dbing 11分前

Love your valuation post as well. I think are right on.

👍️ 3

dbing 14分前

Oh thank you so much.

👍️ 2

dbing 14分前

I’m loading all day tomorrow. Just on my buying this will close over .30.

👍️ 2

ATLnsider 15分前

I posted the link. You only need to download the pdf

👍️0

dbing 17分前

Flipper so u have a copy the judge signed and was issued tonight. I do but don’t seem to be able to cut and paste it to this thread. I can email it to you if you want. It’s MAJOR.

👍️0

dbing 19分前

That’s is tremendous for NWBO. I’m tripling my position of 500k shares tomorrow. .20’s won’t be around for long.

👍️0

flipper44 23分前

The Phunware case, Letter to file Amended complaint from April 18, 2024,
was ordered granted on November 26, 2024.

👍️0

ATLnsider 24分前

Yes it is. Posner is also representing Phunware, and this court ruling, which was filed today (11/26/2024), bodes well for NWBio’s case against the 7 Market Makers (MMs).

The NWBio case is cited several times in this ruling. This tells me, and it should tell the market, that the MTD will be denied:

https://www.courtlistener.com/docket/67634609/34/phunware-inc-v-ubs-securities-llc/

👍️ 1

dbing 29分前

This is HUGE for Nwbo

👍️0

dbing 41分前

Phunware Loss Causation Decision Dismissing The MTD With No Prejudice to Determining Still Longer Term Damage

👍️ 1

Hopeforthefuture3 49分前

Yes the grade 3 brain cancer patients did very well especially with poly-iclc.
Of the 15 gbm patients one survived 5 years. Of the 5 with vaccine + poly none survived 5 years, one did get past 40 months before passing.
P value on this small trial for including the poly-iclc in addition to vaccine for gbm was 0.95

👍️0

XMaster2023 1時間前

Trying to vilify LP? First of all, no friends or employee of Ken Griffin or any other market maker can do so.

🏆️ 1 👍️ 2

RobotDroid 2時間前

It's a gold mine for LP, the only person benefiting here.

👍️ 1 👿 1 ☠️ 1

Poor Man - 2時間前

That is the bet with owning this stock, that all those things occur.

I’m willing to take a small speculative bet, but more likely to wait until approval before putting more money into this stock.

👍️ 1

GoodGuyBill 2時間前

Your need to refute any statement, even remotely positive, from sources you yourself admit 'nobody ever heard" is very telling...

Longs KNOW what we hold, despite you best efforts.

Carry on. Keep pissing in the wind...

🏆️ 2 👍️ 4 💯 1

theorysuit 2時間前

I don't know there is lot wrong with this company. Where is the money going to come from for a commercial launch? Where is a strategy for this launch and do they have any experience doing so? It might be a moot point if they don't get approval...this thing is DOA.

presumably upfront payments from combo trials and licensing agreements that is a big assumption they are going to get anyone to front them money for trials and licensing. I gotta see the contract with my own eyes before I can believe this carrot they dangle.

👿 1 ☠️ 1

Poor Man - 2時間前

The end of the year tax and wash selling might make matters worse, but the stock price has been on a straight downward trend for at least a year that became worse after the ASM. The reason is the fundamentals, the stock remains traded as an OTC and continues to be diluted via inefficient capital raises. None of this will improve until MHRA approval and presumably upfront payments from combo trials and licensing agreements followed by an uplist, which is not likely until early next year.

We’re headed to 20 cents.

IMO we are seeing just straight up selling vs the idea of buying now and holding for 31 days to avoid the wash

Looks like another year of these grifters underperforming.

👿 2 ☠️ 2

learningcurve2020 3時間前

It's a point that's been known for thirty years. My point is just because folks here highlight a few five year Specials survivors who received SOC plus L doesn't mean that L is necessarily responsible.

👿 2 ☠️ 1

FeMike 3時間前

You just stated that SOC provides 5% five year survival in Europe.

Never mind I understand your point now. Yes excellent point. Too understated actually. The difference in a few percent at the scale of disease we are attacking is way too neglected.

👍️0

brooktrail1933 3時間前

The "10+ year survival" refers to the Grade 3 glioma patients in the trial. A patient with that diagnosis typically lives about 2 years on SOC.

👍️ 3 💯 1

Hopeforthefuture3 3時間前

Well sure hope get the UK approval SOON and then they apply in the EU next. Can perhaps help some of these people especially if can get combination therapy

👍 1

RR6 4時間前

Hey Flip,
FWIW my research of the numbers last year were a bit higher. The estimates were 3 NdGBM cases per 100,000 population. GB has about 68,000,000 in population and the EU has about 450,000,000 according to the census estimates. So, 518,000,000/3 is 15,540; add in Recurrent GBM for a rough x2 and the combined total is 31,000+
Long term the ratio may actually be higher then 3 if we believe the news about turbo cancers, etc.
I have little regard for the management of NWBO, but they just may have both the numbers and the playing field in their favor.

👍 11

learningcurve2020 4時間前

Hey, I'm not the one on my 99th flop with a seemingly indefinite timeline.

👿 1 ☠️ 1

jtaylor042 4時間前

Holidays around the NWBO Board.

👍️0

learningcurve2020 4時間前

The number I have is 15,000. But either way, you're ignoring the meaning of my post, as usual.

👿 1 ☠️ 1

flipper44 4時間前

According to available data, approximately 19,000 new glioblastoma (GBM) cases are diagnosed in Europe each year.

You just stated that SOC provides 5% five year survival in Europe.

👍 3 👍️ 4 💯 1

dennisdave 5時間前

Per 10q they are not gonna make any update with regards to MAA. Which one should you believe?
Les stated in the big booz show that they will update us if something was wrong with the MAA, which was the subject.

What is your basis on this? Guesstimate? No I trust Senti's source she has been in contact with the company

That doesn't mean they will be quick with a New Active Substance Marketing Authorisation Applications which DCVax-L is being categorized.
it also doesn't mean that you can drive a car. See we can both make strange connections between two datapoints in what we both never claimed.

👍️ 1 🤣 1

dennisdave 5時間前

Well, one thing we can easily agree on is that if Powers has not arranged a huge upfront payment for using DCVAX IP for the 10Q mentioned joint trials (which I think will be Merck) then she really is the most INcompetent biotech CEO ever to have walked the globe. In that case she will easily risk NWBO's bankruptcy with or without approval, with all their ambitions. Heck going on hand-to-mouth like this for another ....18 months without any other source of substantial non-dilutive cash will kick us into the the abyss.

The binary here is now: DCVAXL approved + large pharma paying a huge upfront payment will get us to $6-$8 billion market cap on a normal exchange.
Anything short of that.... well ... abyss

IMO
.

👍️ 5 🙏 1

dennisdave 5時間前

From my conversation with ChatGTP

You're absolutely correct: for a small biotech company with a single high-stakes drug in its pipeline, the potential approval of its cancer drug is often a make-or-break scenario. Entering into an agreement with a large pharmaceutical company, even one contingent on regulatory approval, may not worsen its situation if the approval fails; the biotech would face significant challenges either way.

Key Considerations for the Biotech
No Downside Beyond Status Quo:

Without approval, the biotech’s IP becomes less valuable or potentially worthless, especially if no alternative indications or follow-up drugs exist. Bankruptcy might be unavoidable. In this light, agreeing to such a deal doesn’t increase the biotech’s risk but instead provides a possible lifeline.

Strategic Partnership Benefits:
If approval is achieved, the partnership could accelerate the drug’s development, market entry, and potential revenue generation.
The agreement may also enhance the biotech’s credibility and investor interest, as a partnership with a large pharmaceutical signals confidence in its IP.
Potential for "Exit"

Opportunity:
Even in the absence of upfront payment, the biotech may view the deal as a precursor to a buyout. If the drug is approved, the large pharma could escalate its involvement, potentially acquiring the biotech outright.

Large Pharma Perspective
From the pharmaceutical company’s standpoint, the arrangement minimizes risk while positioning the company to benefit significantly if the drug succeeds. By avoiding an upfront payment:

The large pharma avoids tying up resources in an uncertain asset.
It gains strategic access to the biotech’s IP without committing fully until approval, making it a calculated but low-risk move.

Conclusion
Such deals reflect asymmetric risk-sharing: the small biotech assumes almost all of the pre-approval risk, while the large pharma stands to benefit significantly with little initial commitment. For the biotech, this type of agreement could be seen as a calculated gamble—it risks losing nothing beyond the status quo but could gain everything if approval is secured. This is especially appealing for cash-strapped companies with limited alternatives.

👍️ 1 🙏 1

dstock07734 5時間前

Why did you not mention that poly-iclc group has better OS and PFS?

How about talking about whether in the following trial the DC vaccine used to treat three tough pediatric cold tumors is basically the same as DCVax-L in terms of pulsing dendritic cells with tumor lysate? You claim you are a long, right? Should you feel excited if the technology tested in the trial is the same as DCVax-L?

See how dire was the situation for patient #2? She had cancer spread on her kidney, bone, bone marrow, and lungs. But after receiving the treatment, she was cancer free four and half years after the treatment.

Keep in mind this is not about Direct.

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
https://clinicaltrials.gov/study/NCT00923351

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
https://aacrjournals.org/clincancerres/article/22/13/3182/79179/Adjuvant-Immunotherapy-to-Improve-Outcome-in-High

🏆️ 1 👍️ 3

sharpie510 5時間前

Yes, great news for Joel! And Dr. Bosch has stated, when you take DCVax-L your expected survival time increases dramatically the longer you stay alive.
💪
22m:50s mark
https://vimeo.com/273334745

👍 6 💥 4

RobotDroid 5時間前

More BS posted that means absolutely nothing. You clowns are really reaching now.

👍️ 1 👿 1 ☠️ 1

RobotDroid 5時間前

Anything Les says is random blathering of a fading mind. I liken Les to Homer Simpson, only Homer is smarter. Many here forget how many times he has lied, the latest being 'fall'. LP has told the most lies, I think she gets paid per BS statement.

👍️ 1 👿 1 ☠️ 1

learningcurve2020 5時間前

Each year in Europe about 1,000 SOC GBM patients make the five year mark.

👿 1 ☠️ 1

Zadie420 5時間前

Great post. Glad to see Joe has a good quality of life. This is what’s all about. Hopefully I near future with what we have in pipeline Joe won’t worry about brain cancer coming back. Let’s all pray for all cancer patients on thanksgiving day and pray we get approval so other improved treatments can star treating other cancer patients.

👍️ 3

flipper44 5時間前

Over five years since diagnosis.🙂

👍️ 5

Red_Right_Hand 5時間前

https://www.barchart.com/story/news/29772004/cancer-vaccines-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-dendreon-pharma-candel-therapeutics-glaxosmithkline-merck-aduro-biotech-astrazeneca-plc-dendreon

Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others

Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others

👍️ 14

sharpie510 5時間前

https://x.com/sharpie510/status/1861537155165888706

Quality of Life matters. One simply cannot live the way Joel has lived if tethered to an Optune device 24/7.

Today
by Elisa Bonaminio, Organizer
November 2024
Another six months has gone by since we last updated you. And so, it’s been scan time again. We’re delighted that things are stable and we’ve had a busy summer. Joel finished the first year of his Master’s and continued to work at APC. However, we managed to have two great holidays. In August we went to the Edinburgh Fringe Festival and saw an amazing variety of plays and comedy. We all love going to the theatre and enjoyed the beautiful city.

In September we went to Kalkan in Turkey, thanks to our generous friends, who let us stay in their apartment. It’s a beautiful place and we had a mixture of relaxation and visiting incredible sights, such as the Salkikent Gorge.

The day after the scan results, Joel moved house again and we are all thrilled that he is now living with two of his oldest and closest friends – in fact one of them is only six hours older than him and they have grown up together.

After Turkey, Joel started back at university to complete the final year of his Master’s. He’s already started planning what he wants to write about for his thesis.

We had an amazingly special weekend celebrating Steph’s dad’s 94th birthday and all the family got together for a special lunch. There were 17 of us and it was really fantastic to all be together.

Of course, the worry of Joel’s brain cancer returning is ever present. It never goes away. But it’s so lovely to see him making the most of life and spending as much time with him as we can. Ian and Steph

👍️ 16 ❤️ 6

martyDg 6時間前

Approvals any day. MTD any day. Buyout any day. WTF.

Only the cult followers of LP always post that crap.

👿 1 ☠️ 1

martyDg 6時間前

Les has stated that if there are problems they will let us know

Per 10q they are not gonna make any update with regards to MAA. Which one should you believe? A senile Les who most of the time doesn't know what he's talking about or a factual document?

NWBO inspections are at its end What is your basis on this? Guesstimate?

the MHRA has made it clear that they have no more delays That doesn't mean they will be quick with a New Active Substance Marketing Authorisation Applications which DCVax-L is being categorized.

👍️ 1 👿 1 ☠️ 1

learningcurve2020 6時間前

This would be a good time for LP to announce a DEI initiative.

👿 1 ☠️ 1

Hopeforthefuture3 6時間前

Ilovetech - did you have a paper with these statistics - if so I would like to read it

ilovetech, you posted the following:
"The company knows, those paying attention know, that the company has moved on to second gen, known to us as the 10+ year survival (dcvax/combo) we've already seen in a 13 year old trial." ( post #734163)

What is this 10+ year survival trial? Did I miss some published study?
If you are talking about the trial published in nature communications from online publish date of May 08 2024 (first author Richard G. Everson, last authors Liau and Prins) you may want to read a bit closer. The study was comparing ATL-DC vs ATL-DC combined with either poly-ICLC or resiquimod. On page 7 in figure 3b you can see there were a total of 15 gbm patients in the trial and 1 survived to 60 months. That 1 was on the ATL-DC without the immune stimulating adjuvants. The p value on the graph on gbm for the adjuvants is shown as p=0.93.
I have read numerous posts about long term gbm survival but am uncertain of the source - can you share?

👿 1 ☠️ 1

manibiotech 6時間前

All my predictions over last 2 years have been spot on
Going down as predicted till next support

NWBO inspections are at its end

Again you keep using this as a point of fact. It’s not.

I agree with the assumption. But don’t act like we know for sure this is true.

👍️ 1 👿 1 🚽 1 ☠️ 1

martyDg 6時間前

The deal which I think is with Merck depends solely on UK approval. NO UK approval? then the contract is probably stipulating that it's void and worthless and can be thrown in the bin

Imo, that's a flawed theory. Why would NWBO accept that condition? It's ridiculous. If Merck can make the deal null and void upon UK MAA rejection, then NWBO can obviously void the deal upon approval, since they can shop around for a partnership. Without sealing any deals before approval, both parties can nullify the unsealed deals. Why would Merck risk the possibility? Therefore, I believe there's no deal in place yet.

👿 1 ☠️ 1

FeMike 6時間前

Your claim that they are waiting until after the FDA has approved DCVAXL's BLA is absurd as well since the 10Q clearly indicated

With the strawmen, DD.

I am in no way claiming that we are waiting for for BLA/FDA approval. Stop taking that out of context.

The difference between us is that you are for some reason absolutely committed to proving me wrong.

I'm not trying to prove you wrong. I fully concede you may be right.

I simply disagree with you from the angle of 'we are both in the dark and trying to figure out what is going on' and am trying explain why my conclusion differs from yours. I'm not saying you are right or I am right. I'm just sharing my perspective and opinion and you are vehemently trying to tell me I am without a doubt, indisputably, wrong.

👿 2 🚽 1 ☠️ 2

dennisdave 6時間前

what I wild is that you would rather take one anecdotal case lykiri brought forward and then base your Q2 2025 as the most likely MHRA decision timeline than tunnelvisionofplenty calculation with a dozen MAAs. As if there have never been more than one or two CHM meetings, objections, two RFI's clock off period etc at the MHRA for a certain troubled MAA of another biotech, of course there has. Your baseless suggestion that therefore NWBO is also delayed is absurd. Its children's statistics.

- Les has stated that if there are problems they will let us know
- NWBO inspections are at its end
- NWBO stated in the last 10Q they expect Direct early 2025
- the MHRA has made it clear that they have no more delays

But sure there was a troubled MAA that took 1.5 years therefore MAA NWBO etc. You are entitled to your own opinion

👍 2

ilovetech 6時間前

KG loves it, when big thinkers like you provide him with a big fat smoke screen. No wonder he's so comfortable bragging about setting equity prices, exactly where he thinks they belong, and not supply and demand. You do you. Good job.

👍️ 1

iclight 6時間前

Pretty sure the P3 started before Guns and Roses released Patience in 1989.

👍️ 1 👿 1 ☠️ 1

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター